Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Institute of Hematology and Medical Oncology "L and A Seràgnoli", University of Bologna, Italy.
Giovanni
G
Martinelli
Michele
M
Malagola
Emanuela
E
Ottaviani
Gianantonio
G
Rosti
Elena
E
Trabacchi
Michele
M
Baccarani
D000368:Aged; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005091:Exons / Q000235:genetics; D018922:HL-60 Cells; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors* / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012074:Remission Induction; D039221:mRNA Cleavage and Polyadenylation Factors / Q000037:antagonists & inhibitors* / Q000235:genetics*
D001549:Benzamides; D004791:Enzyme Inhibitors; C479818:FIP1L1 protein, human; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha